Schizophrenia & Other Psychotic Disorders
Commentary
Will changing the names of psychiatric medications lead to better treatment?
Dr. Robert T. London wonders whether the new Neuroscience-based Nomenclature Project will be good for patient care.
Commentary
Psychodiagnostic testing services: The elusive quest for clinicians
Imagine the clinical care consequences if patients seen in specialty or primary care practices did not have ready access to laboratory, other...
Conference Coverage
Agitation in psychosis: Still no ‘magic bullet’
SAN DIEGO – Some evidence supports various treatments, including antipsychotics, Dr. Marc Agronin said.
FDA/CDC
FDA approves transdermal asenapine system for schizophrenia
This approval marks the first transdermal patch formulation of an antipsychotic for treatment of schizophrenia.
From the Journals
Schizophrenia patients have ‘aberrant’ response to Epstein-Barr
Individuals with schizophrenia appear to express atypical proportions of antibodies to the virus.
From the Journals
Patients with nonaffective psychosis offer treatment target preferences
Most of the patients wanted at least one of the eight problem areas assessed in the study treated, and on average, they wanted more than four...
Conference Coverage
New themes emerging about antipsychotic maintenance therapy
COPENHAGEN – “Polypharmacy might not be so bad.” – Dr. Mark Weiser
From the Editor
Premature mortality across most psychiatric disorders
Psychiatric brain disorders are associated with multiple medical diseases that lead to a shorter lifespan.
Cases That Test Your Skills
The 84-year-old state boxing champ: Bipolar disorder, or something else?
Mr. X, age 84, presents with mania-like symptoms, grandiose delusions, and psychotic symptoms that began 2 weeks ago. What could be the cause of...
From the Journals
Four genetic variants link psychotic experiences to multiple mental disorders
Schizophrenia might not be sole driving force behind psychosis
Conference Coverage
Lumateperone for schizophrenia shows safety, tolerability in long-term study
COPENHAGEN – One-quarter of patients showed clinically meaningful weight reduction.